Thrombosis and embolism in patients with chronic kidney disease

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Currently, chronic kidney disease makes a significant contribution to the general structure of the incidence of the population. The presence of chronic kidney disease several times increases the risk of vascular complications. Thromboembolic complications are one of the most common causes of death from vascular diseases. Chronic kidney disease increases the risk of deep vein thrombosis as a risk factor for pulmonary embolism in people with end-stage renal disease. The coagulation cascade is a complex process involving platelets, endothelial cells, and coagulation factors. In clinical practice, patients with end-stage renal disease often have a tendency to bleed, but thrombotic events such as arteriovenous fistula thrombosis, peripheral arterial occlusive disease and deep vein thrombosis have also been noted. In nephrotic syndrome and membranous nephropathy, venous thrombosis of the lower extremities and renal veins is common. An important role in the occurrence of thrombosis in nephrotic syndrome is played by antithrombin III, which is synthesized mainly in the vascular endothelium, liver and lung tissue. In patients with thrombosis, the recovery of antithrombin III activity is reduced. Factors contributing to the development of thrombosis and embolism in chronic kidney disease are nephrotic proteinuria, decreased levels of albumin, antithrombin III, blood protein C, and atherogenic dyslipidemia. An increase in the concentration of homocysteine, C-reactive protein and blood fibrinogen makes an additional contribution to the formation of thromboembolic complications in patients with chronic kidney disease. The review article provides an overview of clinical trials aimed at analyzing risk factors for the development of thrombosis and embolism in patients with chronic kidney disease.

全文:

受限制的访问

作者简介

Ilkhom Murkamilov

I.K. Akhunbaev Kyrgyz State Medical Academy; SEI HPE Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B.N. Yeltsin

编辑信件的主要联系方式.
Email: murkamilov.i@mail.ru
ORCID iD: 0000-0001-8513-9279

Dr. Sci. (Med.), Associate Professor at the Department of Faculty Therapy, I.K. Akhunbaev KSMA, Associate Professor at the Department of Therapy No.2, KRSU named after B.N. Yeltsin

吉尔吉斯斯坦, Bishkek; Bishkek

Viktor Fomin

FSAEI HE First Moscow State Medical University named after I.M. Sechenov (Sechenov University)

Email: fomin_vic@mail.ru
ORCID iD: 0000-0002-2682-4417

Corresponding Member of RAS, Dr. Sci. (Med.), Professor, Head of the Department of Faculty Therapy No. 1, N.V. Sklifosovsky Institute of Clinical Medicine, Vice-Rector for Innovation and Clinical Activities, Sechenov University

俄罗斯联邦, Moscow

Ibragim Sabirov

SEI HPE Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B.N. Yeltsin

Email: sabirov_is@mail.ru
ORCID iD: 0000-0002-8387-5800

Dr.Sci. (Med.), Professor, Head of the Department of Therapy No. 2 of the Medical Faculty, KRSU named after B.N. Yeltsin

吉尔吉斯斯坦, Bishkek

Zina Satkynalieva

I.K. Akhunbaev Kyrgyz State Medical Academy

Email: murkamilov.i@mail.ru
ORCID iD: 0000-0002-1019-8562

Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy of the I.K. Akhunbayev KSMA

吉尔吉斯斯坦, Bishkek

Furkat Yusupov

Osh State University

Email: furcat_y@mail.ru
ORCID iD: 0000-0003-0632-6653

Dr.Sci. (Med.), Professor, Head of the Department of Neurology, Neurosurgery and Psychiatry of the Medical Faculty, Osh State University, Chief Neurologist of the Southern Region of Kyrgyzstan

吉尔吉斯斯坦, Osh

参考

  1. Kumar D.R., Hanlin E., Glurich I., et al. Virchow’s contribution to the understanding of thrombosis and cellular biology. Clin. Med. Res. 2010;8(3–4):168–72. https://doi.org/10.3121/cmr.2009.866
  2. Бокерия Л.А., Затевахин И.И., Кириенко А.И. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2015;4(2):52. [Bokeria L.A., Zatevahin I.I., Kirienko A.I., et al. Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiya. 2015;4(2):52 (In Russ.)].
  3. Kearon C., Kahn S.R. Long-term treatment of venous thromboembolism. Blood J. 2020;5(135):317–25.. https://doi.org/10.1182/blood.2019002364
  4. Тромбоз и тромбоэмболия почечных артерий: потенциально контролируемая опасность. От редакции. Клиническая нефрология. 2011;3:22–5. [Renal artery throbosis and thrombembolism: danger, thart must be controlled. From the editors. Clinical Nephrology. 2011;3:22–5 (In Russ.)].
  5. Liu Z., Zhang L., Li L., et al. MP57-06 Bland thrombus as an independent risk factor for survival implications in renal cell carcinoma with venous tumor thrombus. J. Urol. 2020;203:(Suppl. 4):e859–61. https://doi.org/10.1097/ JU.0000000000000926.06
  6. Козловская Н.Л., Боброва Л.А. Тромбоз почечных вен. Клиническая нефрология.2012;1:4–9. [Kozlovskaya N.L., Bobrova L.A. Renal vein thrombosis. Clinical Nephrology. 2012;1:4–9 (In Russ.)].
  7. Sharp W., Olivero J.J. Venous Thrombosis in Nephrotic Syndrome. Method. Debakey Cardiovasc. J. 2018;14(3):237–38. https://doi.org/10.14797/mdcj-14-3-237
  8. Zou H., Li Y., Xu G. Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy. BMC. Nephrol. 2019;20(1):442. https://doi.org/https://doi.org/10.1186/s12882-019-1637-y
  9. Jie H.U., Jie Y., Sun J. Mechanism and treatment of coagulation disorder in membranous nephropathy. Med. J. Chin. People's Liberat. Army. 2019;44(3):266–70. https://doi.org/10.11855/j.issn.0577-7402.2019.03.14
  10. Paulose B.K. Brachial arterial thrombosis as the presenting symptom in an adult idiopathic membranous nephropathy-a case report. Univer. J. Med. Medical Special. 2019;5(5).
  11. Togashi H., Shimosato Y., Saida K., et al. Childhood Nephrotic Syndrome Complicated by Catastrophic Multiple Arterial Thrombosis Requiring Bilateral Above-Knee Amputation. Frontiers in Pediatr. 2020;8:107. https://doi.org/10.3389/fped.2020.00107
  12. Ismail G., Obrișcă B., Jurubiță R., et al. Inherited Risk Factors of Thromboembolic Events in Patients with Primary Nephrotic Syndrome. Med. 2020;56(5):242. https://doi.org/10.3390/medicina56050242
  13. Толстова Е.М., Эмирова Х.М. Ретроспективная оценка и катамнестическое наблюдение пациентов, перенесших тромбоз почечных вен в неонатальном периоде. Российский вестник перинатологии и педиатрии. 2017;62(4):249–53. [Tolstova E.M., Emirova H.M. Retrospective assessment and follow-up of patients who underwent renal vein thrombosis in the neonatal period. Ros. Vestn. Perinatal. Pediatr. 2017;62(4):249–53 (In Russ.)].
  14. Donato H. Trastornos trombуticos. In: H. Donato, M.C. Rapetti, eds. Hematologia Neonatal. Buenos Aires: Fundasap. 2007. P. 255–77.
  15. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J. Vascular. Sur. 2007;45(1):S5–67. https://doi.org/10.1016/j.jvs.2006.12.037
  16. Simon S.P., Thomas J. Coagulopathy in the nephrotic syndrome. Saudi J. Kidney Dis. Transplant. 2020;31(2):545–48. http://www.sjkdt.org/text.asp?2020/ 31/2/545/284035
  17. Kara H. Internal Jugular Vein Thrombosis due to Chronic Kidney Disease: A Case Report. Ann. Vascular. Surg. 2020;62(500):e1–500. e3. https://doi.org/10.1016/j.avsg.2019.08.074
  18. Bashir R., Tinkel J., Malhotra D. Renal vein thrombosis: a case report. Angiology. 2007;58(5):640–43. https://doi.org/10.1177/0003319707303646
  19. Decoster T., Schwagten V., Hendriks J., Beaucourt L. Renal colic as the first symptom of acute renal vein thrombosis, resulting in the diagnosis of nephrotic syndrome. Eur. J. Emerg. Med. 2009;16(4):170–71.
  20. Zhang Y., Wang Y., Li J., Cai S. Color Doppler Ultrasound Diagnosis of Intrarenal Vein Thrombosis: A Rare Case Report and Literature Review. Medicine (Baltimore). 2018;97(13):e0284. https://doi.org/10.1097/MD.0000000000010284
  21. Бобкова И.Н., Козловская Л.В., Цыгин А.Н., Шилов Е.М. Клинические рекомендации по диагностике и лечению мембранозной нефропатии. Нефрология. 2014;18(4):93–100. [Bobkova I.N., Kozlovskaya L.V., Cygin A.N., Shilov E.M. Clinical practice guidelines for diagnosis and treatment membranous nephropathy. Nephrol. (Saint-Petersburg). 2014;18(4):93–100 (In Russ.)].
  22. Wang Y., Zhang J., Zhao L., et al. Acute arterial thrombosis in a patient with nephrotic syndrome and antithrombin deficiency on steroid therapy: A case report and literature review. Ann. Vascular. Surg.-Brief Rep. Innovat. 2023;3(1):100152. https://doi.org/10.1016/j.avsurg.2022.100152
  23. Lin R., McDonald G., Jolly T., et al. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney Intern. Rep. 2019;5(4): 435–47. https://doi.org/10.1016/j.ekir.2019.12.001
  24. Воробьева Н.А. Роль антитромбина в диагностике и интенсивной терапии острого ДВС-синдрома (обзор литературы и данные реальной клинической практики). Атеротромбоз.2017;2:53–69. [Vorobieva N.A. Role of antithrombin in diagnostics and intensive therapy of acute dic-syndrome (review of literature and evidence of actual clinical practice). Aterothromb. 2017;2:53–69 (In Russ.)].
  25. Зубаиров Д.М. Молекулярные основы свертывания крови и тромбообразования. Казань, 2000. 362 с. [Zubairov D.M. Molecular basis of blood coagulation and thrombosis. Kazan, 2000. 362 p. (In Russ.)].
  26. Sawetaji J.S., Kant R., Saluja D., Aggarwal K.K. Identification of thrombin inhibiting antithrombin-III like protein from Punica granatum using in silico approach and in vitro validation of thrombin inhibition activity in crude protein. Nat. Prod. Res. 2023;1–13. https://doi.org/10.1080/14786419.2023.2169919
  27. Obeagu E.I., Nwosu D.C., Obeagu G.U. Antithrombin III: A Review. Int. J. Curr. Res. Biol. Med. 2022;7(2):20–7. http://dx.doi.org/10.22192/ijcrbm.2022.07.02.002.
  28. El Ghannam M.Z., Ali E.M., El Samanoudy M.I., Kamel A.R. Assessment of The Level of Protein C in Children with Nephrotic Syndrome. Egypt. J. Hospital Med. 2019;76(3):3828–34. https://doi.org/10.12816/EJHM.2019.41345
  29. Mansour E., Isaeva A. Arterial Thrombus in a Protein C Deficient Patient. Cureus. 2019;11(11):e6130. https://doi.org/10.7759/cureus.6130.
  30. Awotoye J., Fashanu O.E., Lutsey P.L., et al. Resting heart rate and incident venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis. Open Heart. 2020;7(1). http://dx.doi.org/10.1136/openhrt-2019-001080
  31. Смирнов А.В. Дислипопротеидемия как один из неиммунных механизмов прогрессирования склеротических процессов в почечной паренхиме. Нефрология. 1997;1(2):7–12. https://doi.org/10.24884/ 1561-6274-1997-1-2-7-12. [Smirnov A.V. Dislipoproteinemia as nonimmune mechanism of the progression of renal parenchymal sclerosis. Nephrol. (Saint-Petersburg).1997;1(2):7–12. https://doi.org/ 10.24884/ 1561-6274-1997-1-2-7-12 (In Russ.)
  32. Russo G., Piscitelli P., Giandalia A., et al. Atherogenic dyslipidemia and diabetic nephropathy. J. Nephrol. 2020;1–8. https://doi.org/10.1007/ s40620-020-00739-8
  33. Зелинский В.А., Исаулов О.В., Мельников М.В. Тромбоз артерий таза и нижних конечностей при кальцинозе абдоминальной аорты: особенности клинического течения и тактики лечения. Кубанский научный медицинский вестник. 2013;4(139):58–62. [Zelinskiy V.A., Isaulov O.V., Melnikov M.V. Pelvic and low limb arteries thrombosis in patients with an abdominal aortic calcification: clinical manifistation and treatment strategy. Kuban Sci. Med. Bull. 2013;4(139):58–62 (In Russ.)].
  34. Raj D.S., Pecoits-Filho R., Kimmel P.L. Inflammation in chronic kidney disease. Chron. Renal. Dis. Acad. Press. 2020. Р. 355–73. https://doi.org/10.1016/B978-0-12-815876-0.00024-3
  35. Satish M., Agrawal D.K. Atherothrombosis and the NLRP3 inflammasome – endogenous mechanisms of inhibition. Translat. Res. 2020;215:75–85. https://doi.org/10.1016/ j.trsl.2019.08.003
  36. Воробьева Е.Н., Шумахер Г.И., Хорева М.А., Осипова И.В. Дисфункция эндотелия – ключевое звено в патогенезе атеросклероза. Рос. кардиол. журн. 2010;(2):84–91. https://doi.org/10.15829/1560-4071-2010-2-84-91. [Vorobyeva E.N., Shumakher G.I., Khoreva M.A., Osipova I.V. Endothelial dysfunction – a key factor in atherosclerosis pathogenesis. Rus. J. Cardiol. 2010;(2):84–91. https://doi.org/10.15829/ 1560-4071-2010-2-84-91 (In Russ.)].
  37. Neubauer K., Zieger B. Endothelial cells and coagulation. Cell Tiss. Res. 2022;387(3):391–98. https://doi.org/10.1007/s00441-021-03471-2
  38. Zhang Y., Wang M., Jing X., et al. Endothelial function and arterial stiffness indexes in subjects with carotid plaque and carotid plaque length: A subgroup analysis showing the relationship with hypertension and diabetes. J. Stroke Cerebrovasc. Dis. 2023;32(3):106986. https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.106986
  39. Ciccarelli G., Conte S., Cimmino G., et al. Mitochondrial Dysfunction: The Hidden Player in the Pathogenesis of Atherosclerosis? Intern. J. Mol. Sci. 2023;24(2):1086. https://doi.org/10.3390/ijms24021086
  40. Koschinsky M.L. Lipoprotein (a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. Curr. Atheroscler. Rep. 2005;7(5):389–95. https://doi.org/10.1007/s11883-005-0052-y
  41. Hu Q., Chen Y., Deng X., et al. Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation. Biomed. Pharmacother. 2023;159:114252. https://doi.org/10.1016/j.biopha.2023.114252.
  42. Davenport A.P., Hyndman K.A., Dhaun N., et al. Endothelin. Pharmacol. Rev. 2016;68(2):357–418. https://doi.org/10.1124/ pr.115.011833
  43. Стаценко М.Е., Деревянченко М.В. Роль системного воспаления в снижении эластичности магистральных артерий и прогрессировании эндотелиальной дисфункции у пациентов артериальной гипертензией в сочетании с ожирением, сахарным диабетом 2 типа. Российский кардиологический журнал. 2018;23(4):32–6. https://doi.org/10.15829/1560-4071-2018-4-32-36. [Statsenko M.E., Derevyanchenko M.V. The role of systemic inflammation in reducing the elasticity of the main arteries and the progression of endothelial dysfunction in patients with arterial hypertension in combination with obesity, type 2 diabetes. Russ. J. Cardiol. 2018;23(4):32–6 (In Russ.)].
  44. Martella B.M., Veiga G.R.L., Alves B.C., et al. The importance of homocysteine levels in the prognosis of patients with chronic renal disease and in hemodialysis patients. J. Brasil. Patol. Med. Lab. 2018;54(3):170–76. https://doi.org/10.5935/1676-2444.20180030
  45. Лебеденкова М.В. Клиническое значение гипергомоцистеинемии в прогрессировании нефропатий (Обзор литературы). Нефрология и диализ. 2006;4(8):329–35. [Lebedenkova M.V. Clinical value of hyperhomocysteinemia for progressing nephropathy in children (Review). Nephrol. Dial. 2006;4(8):329–35 (In Russ.)].
  46. Wang J., Dudman N., Wilcken D. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb H.aemost.1993;70(06):1047–52. https://doi.org/10.1055/s-0038-1649723
  47. Коломыйцева М.Н., Гасанов М.З., Батюшин М.М. Вклад системного воспаления в развитие сосудистого ремоделирования у пациентов с хронической болезнью почек и саркопенией. Терапия. 2021;5:39–46. https://doi.org/10.18565/therapy.2021.5.39-46. [Kolomyitseva M.N., Gasanov M.Z., Batyushin M.M. Contribution of systemic inflammation to the development of vascular remodeling in patients with chronic kidney disease and sarcopenia. Therapy. 2021;5:39–46. https://doi.org/10.18565/therapy.2021.5.39-46 (In Russ.)].
  48. Муркамилов И.Т., Айтбаев К.А., Фомин В.В. и др. Гомоцистеин и риск нефроцереброваскулярных заболеваний. Sci. Heritage. 2020;50(2):29–35. [Murkamilov I., Aitbaev K., Fomin V., et al. Homocystein and risk of nephrocerebrovascular diseases. Sci. Heritage. 2020;50(2):29–35 (In Russ.)].
  49. Undas A., Brożek J., Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb. Haemostas. 2005;94(11):907–15. https://doi.org/10.1160/TH05-05-0313
  50. Hensen A.D., Lijfering W.M., Cannegieter S.C., et al. Hyperhomocysteinaemia and the risk of recurrent venous thrombosis: results from the MEGA follow‐up study. Br. J. Haematol. 2019;187(2):219–26. https://doi.org/10.1111/bjh.16075/
  51. Пантелеев М.А., Котова Я.Н., Токарев А.А., Атауллаханов Ф.И. Механизмы регуляции свертывания крови. Тер. архив. 2008;80(7):88–91. [Panteleev M.A., Kotova Y.N., Tokarev A.A, Ataullakhanov F.I. Blood coagulation regulation mechanisms. Ther. Arch. 2008;80(7):88–91 (In Russ.)].
  52. Zhang X., Zhang C., Wang B., et al. Congenital fibrinogen disorders with repeated thrombosis. J. Thromb. Thrombolys. 2020;49(2):312–15. https://doi.org/10.1007/s11239-019-01958-y
  53. Chi G., Gibson C.M., Liu Y., et al. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am. J. Hematol. 2019;94(1):21–8. https://doi.org/10.1002/ajh.25296
  54. Mirrakhimov A.E., Ali A.M., Barbaryan A., et al. Primary Nephrotic Syndrome in Adults as a Risk Factor for Pulmonary Embolism: An Up-to-Date Review of the Literature. Int. J. Nephrol. 2014;2014:916760.
  55. Sharp W., Olivero J.J. Venous Thrombosis in Nephrotic Syndrome. Method. Debakey Cardiovasc. J. 2018;14(3):237–8. https://doi.org/10.14797/ mdcj-14-3-237
  56. Li D., Zhang X., Zhang H., Li X. Synergic effect of GPIBA and von Willebrand factor in pathogenesis of deep vein thrombosis. Vascular. 2020. P. 1708538119896446.
  57. Peng X., Wang X., Fan M. et al. Plasma levels of von Willebrand factor in type 2 diabetes patients with and without cardiovascular diseases: A meta‐analysis. Diab. Metab. Res. Rev. 2020;36(1):С.e3193.
  58. Бабичев А.В. Роль эндотелия в механизмах гемостаза. Педиатр. 2013;4(1):122–7. [Babichev A.V. The role of endothelium in hemostasis mechanisms. Pediatr. 2013;4(1):122–7 (In Russ.)].
  59. Habib A., Petrucci G., Rocca B. Pathophysiology of thrombosis in peripheral artery disease. Curr. Vascular. Pharmacol. 2020;3(18):204–14. https://doi.org/10.2174/ 1570161117666190206234046.
  60. Leslom A.N., Alrawiah Z.M.S., Al-Asmari A.M.A., et al. Prevalence of pulmonary thromboembolism in nephrotic syndrome patients: A systematic review and meta-analysis. J. Fam. Med. Prim, Care. 2020;9(2):497–501. https://doi.org/10.4103/jfmpc.jfmpc_1076_19
  61. Singh L., Singh G., Dinda A.K. Understanding podocytopathy and its relevance to clinical nephrology. Ind. J. nephrol. 2015;25(1):1–7. https://doi.org/10.4103/0971-4065.134531
  62. Боброва Л.А., Козловская Н.Л. Тромбоэмболические осложнения нефротического синдрома. Тер. архив. 2020;92(6):105–16. https://doi.org/10.26442/00403660.2020.06.000667. [Bobrova L.A., Kozlovskaya N.L. Thromboembolic complications in nephrotic syndrome. Ter. Arkh. 2020;92(6):105–16. https://doi.org/10.26442/00403660.2020.06.000667
  63. Radhakrishnan J. Hypercoagulability in nephrotic syndrome – UpToDate. https://www.uptodate.com/contents/hypercoagulability-in-nephrotic-syndrome.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##